Caris Life Sciences Valuation Estimate
Caris Life Sciences Valuation as of Last Funding Round
Caris Life Sciences Company Overview
Caris Life Sciences is committed to delivering accurate, high-quality, and comprehensive molecular information to cancer patients as well as oncologists in an effort to advance the use of precision medicine. They are of the opinion that a greater understanding of the disease at the cellular level can lead to improved therapeutic choices and breakthroughs. Caris' Precision Oncology Alliance (POA) is a growing network of renowned cancer centers located all over the world that collaborate to enhance precision oncology and biomarker-driven research. The alliance includes prominent healthcare and research institutions such as Hoag, St. Joseph Health, and Duke Cancer Institute.
Caris Life Sciences Valuation History
FAQ
Does Caris Life Sciences have stock?
Yes, Caris Life Sciences and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Caris Life Sciences is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Caris Life Sciences publicly traded?
No, Caris Life Sciences is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Caris Life Sciences stock?
As a privately held company, Caris Life Sciences shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Caris Life Sciences.
What is the stock symbol for Caris Life Sciences?
Caris Life Sciences is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Caris Life Sciences stock on UpMarket?
If you would like to buy shares in Caris Life Sciences, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Caris Life Sciences stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Caris Life Sciences as well.
What is Caris Life Sciences stock price?
The stock price of Caris Life Sciences can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Caris Life Sciences has issued 250 million shares, at the estimated UpMarket valuation of $8.99 billion, each share of Caris Life Sciences stock would be worth $35.97.
How do Caris Life Sciences pre-IPO trades work?
Pre-IPO trades for Caris Life Sciences will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Caris Life Sciences doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Caris Life Sciences going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Caris Life Sciences officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Caris Life Sciences should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Caris Life Sciences with UpMarket?
Exiting your investment in Caris Life Sciences typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Caris Life Sciences shares?
If you own Caris Life Sciences shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Caris Life Sciences?
UpMarket’s valuation estimate for Caris Life Sciences is algorithmically generated based on recent primary round financings by Caris Life Sciences, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Caris Life Sciences could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
UpMarket was founded in 2019 and has helped hundreds of investors access alternative investments. UpMarket is a licensed broker-dealer based in the United States. UpMarket customers have invested over $150 million in pre-IPO companies, hedge funds, private equity, real estate, and other alternatives.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Caris Life Sciences,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Caris Life Sciences Management
| Name | Position |
|---|---|
| David Halbert | CEO |
| Michael Korn | CMO |
| Reagan Tully | CMO |
